Skip to main content

Cepheid Shares Rise Following NEJM Study on TB Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A study appearing in the Sep. 9 issue of the New England Journal of Medicine has reported unprecedented sensitivity and specificity achieved by Cepheid's new molecular tuberculosis test, driving the company's stock up around 9 percent today.

In mid-afternoon trading, Cepheid shares rose to $17.25, following the publication online yesterday of a study in NEJM in which researchers reported that Cepheid's Xpert MTB/RIF test successfully identified 98.2 percent of all cultured-confirmed TB cases, including more than 90 percent of those with smear-negative disease.

In addition, the PCR-based test had a 97.6 percent success rate in detecting patients with resistance to the anti-TB drug rifampin. Test results were achieved in less than two hours.

The test, designed to be used on Cepheid's GeneXpert system, was co-developed with the Foundation for Innovative New Diagnostics and the University of Medicine and Dentistry of New Jersey. The National Institute of Allergy & Infectious Diseases provided additional funding as did the Bill and Melinda Gates Foundation.

In a statement, NIAID said that in 2008 more than 1.8 million people worldwide died from TB. The number of drug-resistance cases is increasing, as well. "New, less costly tools to rapidly diagnose TB and its drug-resistant forms are urgently needed to help stem the tide of new infections," the institute said.

Separately, Cepheid said the test could have particular implications in developing nations in sub-Saharan Africa and Southeast Asia, where TB and HIV are closely linked.

According to David Persing, chief medical and technology officer for Cepheid, "The Xpert MTB/RIF test is the most technologically advanced test for TB ever developed, yet it is simple enough to perform in all corners of the world, including in resource-limited setting where it is most needed."

The test is CE-IVD marked and is expected to become available in the US within the 2012-2013 timeframe, Cepheid said.


More about the NEJM study can be found in GenomeWeb Daily News' sister publication, PCR Insider.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.